CN102949712A - 一种治疗肿瘤疾病的中西复合药物 - Google Patents
一种治疗肿瘤疾病的中西复合药物 Download PDFInfo
- Publication number
- CN102949712A CN102949712A CN201110249389XA CN201110249389A CN102949712A CN 102949712 A CN102949712 A CN 102949712A CN 201110249389X A CN201110249389X A CN 201110249389XA CN 201110249389 A CN201110249389 A CN 201110249389A CN 102949712 A CN102949712 A CN 102949712A
- Authority
- CN
- China
- Prior art keywords
- medicine
- chinese
- western
- fructus crataegi
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 84
- 239000002131 composite material Substances 0.000 title claims abstract description 19
- 201000010099 disease Diseases 0.000 title claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 8
- 230000001613 neoplastic effect Effects 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 229960000479 ceftriaxone sodium Drugs 0.000 claims abstract description 31
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical group [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 23
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 18
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 18
- 102000004142 Trypsin Human genes 0.000 claims abstract description 18
- 108090000631 Trypsin Proteins 0.000 claims abstract description 18
- 229940111202 pepsin Drugs 0.000 claims abstract description 18
- 229960001322 trypsin Drugs 0.000 claims abstract description 18
- 239000012588 trypsin Substances 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 16
- 239000004615 ingredient Substances 0.000 claims abstract description 12
- 230000029087 digestion Effects 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 11
- 108050006759 Pancreatic lipases Proteins 0.000 claims abstract description 9
- 102000019280 Pancreatic lipases Human genes 0.000 claims abstract description 9
- 229940116369 pancreatic lipase Drugs 0.000 claims abstract description 9
- 210000002784 stomach Anatomy 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims abstract description 6
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 27
- -1 polyethylene Polymers 0.000 claims description 26
- 239000004698 Polyethylene Substances 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 22
- 229920000573 polyethylene Polymers 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 239000008354 sodium chloride injection Substances 0.000 claims description 12
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 11
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 11
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 235000002906 tartaric acid Nutrition 0.000 claims description 11
- 239000011975 tartaric acid Substances 0.000 claims description 11
- 239000004382 Amylase Substances 0.000 claims description 10
- 108010065511 Amylases Proteins 0.000 claims description 10
- 102000013142 Amylases Human genes 0.000 claims description 10
- 235000019418 amylase Nutrition 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 229960001231 choline Drugs 0.000 claims description 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 8
- KUBCEEMXQZUPDQ-UHFFFAOYSA-N hordenine Chemical compound CN(C)CCC1=CC=C(O)C=C1 KUBCEEMXQZUPDQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229930182558 Sterol Natural products 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 230000009514 concussion Effects 0.000 claims description 6
- 201000006549 dyspepsia Diseases 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000011275 oncology therapy Methods 0.000 claims description 6
- 230000000144 pharmacologic effect Effects 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 6
- 150000003432 sterols Chemical class 0.000 claims description 6
- 235000003702 sterols Nutrition 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 4
- 229930024421 Adenine Natural products 0.000 claims description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 4
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 4
- 229930186147 Cephalosporin Natural products 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 102000018832 Cytochromes Human genes 0.000 claims description 4
- 108010052832 Cytochromes Proteins 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 4
- 206010019663 Hepatic failure Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 208000033809 Suppuration Diseases 0.000 claims description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 4
- 235000000431 campesterol Nutrition 0.000 claims description 4
- PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 claims description 4
- 150000003943 catecholamines Chemical class 0.000 claims description 4
- 229940124587 cephalosporin Drugs 0.000 claims description 4
- 150000001780 cephalosporins Chemical class 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000354 decomposition reaction Methods 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 229930003944 flavone Natural products 0.000 claims description 4
- 235000011949 flavones Nutrition 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 229940071490 hordenine Drugs 0.000 claims description 4
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 4
- 229940116298 l- malic acid Drugs 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 208000007903 liver failure Diseases 0.000 claims description 4
- 231100000835 liver failure Toxicity 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229940099690 malic acid Drugs 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229940055695 pancreatin Drugs 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 230000000505 pernicious effect Effects 0.000 claims description 4
- 235000002949 phytic acid Nutrition 0.000 claims description 4
- 239000000467 phytic acid Substances 0.000 claims description 4
- 229940068041 phytic acid Drugs 0.000 claims description 4
- 235000002378 plant sterols Nutrition 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 239000002574 poison Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 210000004915 pus Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 230000026683 transduction Effects 0.000 claims description 4
- 238000010361 transduction Methods 0.000 claims description 4
- 208000009852 uremia Diseases 0.000 claims description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 claims description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 3
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 239000004411 aluminium Substances 0.000 claims description 3
- 230000000711 cancerogenic effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims description 3
- 239000001433 sodium tartrate Substances 0.000 claims description 3
- 229960002167 sodium tartrate Drugs 0.000 claims description 3
- 235000011004 sodium tartrates Nutrition 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 3
- 229940032091 stigmasterol Drugs 0.000 claims description 3
- 235000016831 stigmasterol Nutrition 0.000 claims description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 claims description 3
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 206010001598 Alcohol intolerance Diseases 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 206010061695 Biliary tract infection Diseases 0.000 claims description 2
- 235000017159 Crataegus pinnatifida Nutrition 0.000 claims description 2
- 241000657480 Crataegus pinnatifida Species 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 206010013710 Drug interaction Diseases 0.000 claims description 2
- 206010013911 Dysgeusia Diseases 0.000 claims description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 claims description 2
- KVYNYRIOAYQBFK-UHFFFAOYSA-N Hordatin A Natural products NC(N)=NCCCCNC(=O)C1C2=CC(C=CC(=O)NCCCCN=C(N)N)=CC=C2OC1C1=CC=C(O)C=C1 KVYNYRIOAYQBFK-UHFFFAOYSA-N 0.000 claims description 2
- 229930186391 Hordatine Natural products 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 102000004195 Isomerases Human genes 0.000 claims description 2
- 108090000769 Isomerases Proteins 0.000 claims description 2
- 206010023126 Jaundice Diseases 0.000 claims description 2
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 claims description 2
- 229920000057 Mannan Polymers 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- 206010058674 Pelvic Infection Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 206010061926 Purulence Diseases 0.000 claims description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 210000000683 abdominal cavity Anatomy 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 108090000637 alpha-Amylases Proteins 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 229940076810 beta sitosterol Drugs 0.000 claims description 2
- 108010019077 beta-Amylase Proteins 0.000 claims description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 150000007516 brønsted-lowry acids Chemical class 0.000 claims description 2
- 150000007528 brønsted-lowry bases Chemical class 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 231100000357 carcinogen Toxicity 0.000 claims description 2
- 239000003183 carcinogenic agent Substances 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001076 chlorpromazine Drugs 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 102000038379 digestive enzymes Human genes 0.000 claims description 2
- 108091007734 digestive enzymes Proteins 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- FDRNWTJTHBSPMW-BBJOQENWSA-L disodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-1-oxidoethylidene]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-BBJOQENWSA-L 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 230000035622 drinking Effects 0.000 claims description 2
- 235000019564 dysgeusia Nutrition 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 206010016766 flatulence Diseases 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 210000002618 gastric chief cell Anatomy 0.000 claims description 2
- 210000001126 granulation tissue Anatomy 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 229960004592 isopropanol Drugs 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 230000002366 lipolytic effect Effects 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229960003663 metaraminol Drugs 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 230000000116 mitigating effect Effects 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000014593 oils and fats Nutrition 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 229960002790 phenytoin sodium Drugs 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 229950005143 sitosterol Drugs 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- 150000008130 triterpenoid saponins Chemical class 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 208000012991 uterine carcinoma Diseases 0.000 claims description 2
- 239000002550 vasoactive agent Substances 0.000 claims description 2
- 239000002435 venom Substances 0.000 claims description 2
- 210000001048 venom Anatomy 0.000 claims description 2
- 231100000611 venom Toxicity 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046001 vitamin b complex Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 241001643642 Viticis Species 0.000 claims 1
- 230000002101 lytic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 17
- 230000002147 killing effect Effects 0.000 abstract description 3
- 210000000214 mouth Anatomy 0.000 abstract description 2
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000012010 growth Effects 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 10
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 7
- 201000005619 esophageal carcinoma Diseases 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000007773 growth pattern Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 240000006995 Abutilon theophrasti Species 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 230000004735 virus-associated carcinogenesis Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种治疗肿瘤疾病的中西复合药,其特征在于:它由中药成分和西药成分混合组成,中药成分包括多酶片和健胃消食片,多酶片由胃蛋白酶、胰蛋白酶、胰脂肪酶、胰淀粉酶组成,健胃消食片由太子参、陈皮、山药、麦芽(炒)、山楂组成;西药成分是头孢曲松钠针剂;所述各组分的用量-中药:0.313g/片多酶片5片、计1.57g,0.8g/片健胃消食片1片、计0.8g,西药:0.75g/支头孢曲松钠针剂1支、计0.75g,将以上成分的中、西药物组合,形成一方剂。本发明的一种治疗肿瘤疾病的中西复合药物,特别涉及能够引起人体组织细胞良性肿瘤和恶性肿瘤感染的病原菌进行抑制和杀灭的中西复合药物,当有感染肿瘤时,将复合药直接滴入口腔或患处,每次3-4滴。本药品副作用小,30分钟见效,不会对肝、脑、肾造成伤害。
Description
技术领域
本发明的一种治疗肿瘤疾病的中西复合药物,特别涉及能够引起人体组织细胞良性肿瘤和恶性肿瘤感染的病原菌进行抑制和杀灭的中西复合药物。
背景技术
肿瘤(Tumor)是机体在各种致癌因素作用下,局部组织的某一个细胞在基因水平上失去对其生长的正常调控,导致其克隆性异常增生而形成的新生物。一般认为,肿瘤细胞是单克隆性的,即一个肿瘤中的所有瘤细胞均是一个突变的细胞的后代。一般将肿瘤分为良性和恶性两大类。所有的恶性肿瘤总称为癌症(cancer)。
本世纪以来生物学、分子生物学研究证实许多动物和禽类中存在RNA肿瘤病毒,它们或以水平传播方式从一个动物传给另一个动物;或以垂直传播方式传给子代的生殖细胞和体细胞。前者为外源性感染,后者为内源性感染。70年代发现逆转录酶后把RNA肿瘤病毒归为逆转录病毒科(Retroviridae)肿瘤病毒亚科(Oncovirinae)。在DNA病毒中较早了解的是乳多空病毒可引起恶性和良性肿瘤。当多瘤病毒感染体外培养的细胞后,细胞转化为肿细胞,这在病毒致癌机理的研究中起重要作用。
肿瘤的生长方式:肿瘤可以呈膨胀性生长、外生性生长和浸润性生长。
1)膨胀性生长:是大多数良性肿瘤所表现的生长方式,肿瘤生长缓慢,不侵袭周围组织,往往呈结节状,有完整的包膜,与周围组织分界明显,对周围的器官、组织主要是挤压或阻塞的作用。一般均不明显破坏器官的结构和功能。因为其与周围组织分界清楚,手术容易摘除,摘除后不易复发。
2)外生性生长:发生在体表、体腔表面或管道器官(如消化道、泌尿生殖道)表面的肿瘤,常向表面生长,形成突起的乳头状、息肉状、菜花状的肿物,良性、恶性肿瘤都可呈外生性生长。但恶性肿瘤在外生性生长的同时,其基底部也呈浸润性生长,且外生性生长的恶性肿瘤由于生长迅速、血供不足,容易发生坏死脱落而形成底部高低不平、边缘隆起的恶性溃疡。
3)浸润性生长:为大多数恶性肿瘤的生长方式。由于肿瘤生长迅速,侵入周围组织间隙、淋巴管、血管,如树根之长入泥土,浸润并破坏周围组织,肿瘤往往没有包膜或包膜不完整,与周围组织分界不明显。临床触诊时,肿瘤固定不活动,手术切除这种肿瘤时,为防止复发,切除范围应该比肉眼所见范围大,因为这些部位也可能有肿瘤细胞的浸润。
肿瘤患者的病原体有G-菌,占65.97%,其中大肠埃希菌比例最高为31.25%,其次是肺炎克雷伯菌、铜绿假单胞菌分别为13.89%、12..50%;G+菌占29.17%,其中以金黄色葡萄球菌为主占10.42%。文件名称:肿瘤患者医院感染病原体分析上海冶金研究
纵观恶性肿瘤治疗方法的历史发展与衍变,不难看出,肿瘤外科学、肿瘤放射治疗学、肿瘤化学治疗学构成了现代肿瘤治疗学的三大支柱。三种手段互有特点,互为补充。
从治疗效应看,外科手术和放射治疗都为局部治疗的方法。因此,肿瘤化学治疗专家除了重视局部肿瘤外,更多地把着眼点放在恶性肿瘤的扩散和转移上。他们对于肿瘤治疗的观点为细胞指数杀灭的观点,故强调了多疗程、足剂量的用药方法,以期能彻底杀灭绝大部分的肿瘤细胞。
常用于抗肿瘤抗生素有米托蒽醌、博来霉素、阿霉素、丝裂霉素等和植物来源抗肿瘤药有长春碱、长春地辛、多西紫杉醇等。其不良反应都有骨髓抑制,可引起白细胞和血小板减少,为剂量限制性毒性。还可引起皮疹、呕吐、头痛等症状。
文章“蛋白酶体抑制剂逆转肿瘤多药耐药的研究进展”所述:肿瘤多药耐药是肿瘤治愈的主要障碍之一,许多抗癌药物通过凋亡机制抑制杀伤肿瘤:肿瘤细胞受到抗癌药物的刺激,可引起应激反应,激活抗凋亡程序,减弱药物诱导的凋亡作用,从而产生耐药性,导致化疗失败。蛋白酶体抑制剂可选择性地促进肿瘤细胞凋亡,逆转多药耐药。蛋白酶体被认为是肿瘤治疗的新靶点。
发明内容
本发明的目的,在于提供一种治疗肿瘤疾病的中西复合药物,特别涉及能够引起人体组织细胞良性肿瘤和恶性肿瘤感染的病原菌进行抑制和杀灭的中西复合药物。
本发明的目的是通过以下技术方案实现的。
一种治疗肿瘤疾病的中西复合药,它由中药成分和西药成分混合组成,中药成分包括多酶片和健胃消食片,多酶片由胃蛋白酶、胰蛋白酶、胰淀粉酶、胰脂肪酶组成,健胃消食片由太子参、陈皮、山药、麦芽(炒)、山楂(含酒石酸)组成;西药成分是头孢曲松钠针剂:所述各组分的用量-中药:0.313g/片多酶片5片、计1.57g,0.8g/片健胃消食片1片、计0.8g,西药:0.75g/支头孢曲松钠针剂1支、计0.75g,将以上成分的中、西药物组合,形成一方剂。
1,本发明中治疗肿瘤疾病的西复合药的制备方法如下:
1)首先原料和器具如下:浓度为250ml:2.25g的氯化钠注射液1瓶,5ml及10ml的配药注射器各1个,带橡皮塞的10ml玻璃瓶1个,10ml聚乙烯瓶1个,砸药罐和药勺各1个。
2)取0.313g/片的多酶片5片,用药勺把药片放入砸药罐内,用木棒把药片碾碎成为药粉,倒入10毫升带橡皮塞的玻璃瓶内;再使用10ml注射器分2次吸取6ml氯化钠注射液注入带橡皮塞的玻璃瓶内,用手摇晃使其充分溶解,然后静置30分钟;有沉淀物析出,上部为暗红色的悬乳液-多酶片水溶液,按药片的溶解量20%计算,该药水溶液的浓度为0.1g/ml,用5ml注射器将该药液吸出4ml,注入到10ml的聚乙烯瓶内。
3)取0.75g/支的头孢曲松钠针剂1支,撬掉铝盖,用10ml注射器2次吸入8ml氯化钠注射液注入瓶中,震荡后5分钟,放置48小时后;药液呈现浅红色,其浓度为0.09g/ml,用5ml注射器吸出1.5ml药液注入至步骤2)中所述的1个聚乙烯瓶内,震荡后放置24小时。多酶片中胰蛋白酶、胃蛋白酶与头孢曲松钠发生降解反应生成蛋白酶体,放出气体,其化合物蛋白酶体具有消肿止痛作用。
4)取1片0.8g/片的健胃消食片放入砸药罐内,用木棒把药片碾碎成为药粉,倒入10毫升带橡皮塞的玻璃瓶内,用5ml注射器吸取3ml氯化钠注射液注入玻璃瓶内,用手摇后静止30分钟,有沉淀物析出,上部的悬乳液-健胃消食片颗粒水溶液,按药片的溶解量20%计算,该药液浓度为0.15g/ml。用5ml注射器取出1ml注入至步骤2)中所述的1个聚乙烯瓶内,震荡后放置48小时。消食片中的山楂所含的酒石酸与头孢曲松钠发生中和反应而生成酒石酸钠沉淀物放出热,常温放置30天备用。
验证:头孢曲松钠药液与健胃消食片悬乳液中山楂成分发生反应。取一个10ml聚乙烯瓶,用5ml的注射器吸取3ml氯化钠生理盐水注入另一个聚乙烯瓶内,再用5ml的注射器吸取1ml的头孢曲松钠药液注入聚乙烯瓶内:把凉干的山楂切片,用刀片切成碎片10个,放入聚乙烯瓶内。用力震荡5分钟后加盖放置48小时,可以看到聚乙烯瓶内山楂片的表面有许多小气泡,打开瓶盖时有气体放出。山楂的成分有山楂酸、酒石酸、柠檬酸、苹果酸,其中酒石酸的化学活性较强。可以证明头孢曲松钠药液与健胃消食片悬乳液中山楂中的酒石酸发生反应。
,2,上述的“健胃消食片”系市面购买江西南昌江中药业股份有限公司所生产,“多酶片”系市面购买四川蜀中制药厂所生产,“头孢曲松钠针剂”系市面购买山东鲁抗股份有限公司所生产。
,3,本发明的中药成分多酶片由胃蛋白酶、胰蛋白酶、胰淀粉酶、胰脂肪酶组成,功能主治:用于消化不良,食欲缺乏。中药健胃消食片的主要成分由太子参、陈皮、山药、麦芽(炒)、山楂,功能主治:健胃消食。
1)中药健胃消食片中的山药根茎含多巴胺、儿茶酚胺(catecholamine),以及胆甾醇(cholesterol),麦角甾醇(ergosterol),菜油甾醇(campesterol),豆甾醇(stigmsterol),β-谷甾醇(β-sitosterol)。粘液中含植酸(phytic acid),甘露多糖(mannan)Ia,Ib和Ic;还有三萜皂甙,尿囊素,胆碱(choline),17种氨基酸。
在所有来源于植物种子的油脂中含有甾醇,植物性甾醇不溶于水、酸和碱,但可以溶于乙醚、苯、氯仿、乙酸乙脂、石油醚等有机溶剂。山药甾醇具有阻断致癌物诱发癌细胞形成的功能,β-谷甾醇等植物甾醇对大肠癌、皮肤癌、宫颈癌的发生具有一定程度的抑制作用,疗效很低。
2)中药健胃消食片中的山楂含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等,还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质,所含的解脂酶能促进脂肪类食物的消化。
中药健胃消食片山楂中L-苹果酸可以用于治疗肝病、贫血、免疫力低下、尿毒症、高血压、肝衰竭等多种疾病,并能减轻抗癌药物对正常细胞的毒害作用。
中药健胃消食片山楂中黄酮类化合物含有的牡荆素具有抗癌作用,常用山楂有利于防癌。据报道,山楂片水煎液可延长长瘤动物的寿命,如可抑制小鼠艾氏腹水癌细胞作用,对人的子宫颈癌TCC-26抑制率达70%;鲜山植具抗噬菌体作用,说明有抗癌活性;对子宫癌早期患者恶露不尽,大肠癌等,既能健胃利肠;又有抗癌通淤作用。
3)麦芽主要含α-及β-淀粉酶(amylase),催化酶(catalyticase),过氧化异构酶(peroxidisomerase)另含大麦芽碱(hordenine),大麦芽胍碱(hordatine)A、B,腺嘌呤(ade-nine)胆碱(choline),蛋白质,氨基酸,维生素D、D、E,细胞色素(cytochrome)C。尚含麦芽毒毒,即白栝楼碱(candici-ne)。功效:消食化积;回乳。
4)多酶片是消化酶制剂,每片含胃蛋白酶13克,胰酶300毫克,辅料为硬脂酸镁、滑石粉、邻苯二甲酸二乙脂等。其中胰酶含有胰蛋白酶、胰淀粉酶、胰脂肪酶等组成,通常用于治疗消化酶缺乏的消化不良症。
药理作用:胰脂肪酶能使脂肪分解为甘油及脂肪酸,胰淀粉酶能使淀粉转化为糖,胰蛋白酶能消化溶解变性蛋质,因此,能使脓、痰液、血凝块等分解、变稀,易于引流排除,加速创面净化,促进肉芽组织新生,此外还有抗炎症作用。用于呼吸道疾病,也可用于治疗毒蛇咬伤。胰蛋白酶能使蛋白质转化为蛋白胨;胃蛋白酶(英文名称:Pepsin)是一种消化性蛋白酶,由胃部中的胃粘膜主细胞所分泌,功能是将食物中的蛋白质分解为小的肽片段。胃蛋白酶能使蛋白质转化为蛋白及蛋白胨。
4,头孢曲松钠药理作用:头孢曲松钠的分子式为C18H16N8Na2O7S3?3H2O,分子量为661、59。本品为白色或类白色结晶粉末。本品为长效、广谱头孢菌素,具有很强的杀菌作用。用于敏感致病菌所致的下呼吸道感染、尿路、胆道感染,以及腹腔感染、盆腔感染、皮肤软组织感染、骨和关节感染、败血症、脑膜炎等及手术期感染预防。头孢曲松钠不良反应与治疗的剂量、疗程有关。局部反应有静脉炎(1.86%),此外可有皮疹、头痛或头晕(0.27%),腹泻、恶心、呕吐、腹痛、结肠炎、黄疸、胀气、味觉障碍和消化不良等消化道反应(3.45%)。
药物相互作用:头孢菌素类(注射用头孢曲松钠)静脉输液中加入红霉素、四环素、两性霉素B、血管活性药(间羟胺、去甲肾上腺素等)、苯妥英钠、氯丙嗪、异丙醇、维生素B族、维生素C等时将出现混浊。由于本品的配伍禁忌药物甚多,所以应单独给药。2应用本品期间饮酒或服含酒精药物时在个别病人可出现双硫仑样反应,应避免饮酒和服含酒精的药物。本品与含钙剂或含钙产品合并用药有可能导致致死性事件。
,5,本发明药物的药理作用:多酶片中胰蛋白酶、胃蛋白酶与头孢曲松钠发生降解反应生成蛋白酶体,其功效具有抑制乳多空病毒、大肠埃希菌、肺炎克雷伯菌引起恶性和良性肿瘤。山药中的甾醇类物质和山楂中的黄酮类化合物含有的牡荆素物质与蛋白酶体协同增效,用于治疗水性和脓性肿瘤。胰蛋白酶能消化溶解变性蛋质,因此,能使脓、痰液、血凝块等分解、变稀,易于引流排除。中药健胃消食片山楂中L-苹果酸可以用于治疗肝病、贫血、免疫力低下、尿毒症、高血压、肝衰竭等多种,并能减轻抗癌药物对正常细胞的毒害作用。
具体实施方式
a,首先原料和器具如下:浓度为250ml:2.25g的氯化钠注射液1瓶,5ml及10ml的配药注射器各1个,带橡皮塞的10ml玻璃瓶1个,10ml聚乙烯瓶1个,砸药罐和药勺各1个。
b,取0.313g/片的多酶片5片,用药勺把药片放入砸药罐内,用木棒把药片碾碎成为药粉,倒入10毫升带橡皮塞的玻璃瓶内;再使用10ml注射器分2次吸取6ml氯化钠注射液注入带橡皮塞的玻璃瓶内,用手摇晃使其充分溶解,然后静置30分钟;有沉淀物析出,上部为暗红色的悬乳液-多酶片水溶液,按药片的溶解量20%计算,该药水溶液的浓度为0.1g/ml,用5ml注射器将该药液吸出4ml,注入到10ml的聚乙烯瓶内。
c,取0.75g/支的头孢曲松钠针剂1支,撬掉铝盖,用10ml注射器2次吸入8ml氯化钠注射液注入瓶中,震荡后5分钟,放置48小时后;药液呈现浅红色,其浓度为0.09g/ml,用5ml注射器吸出1.5ml药液注入至步骤2)中所述的1个聚乙烯瓶内,震荡后放置24小时。多酶片中胰蛋白酶、胃蛋白酶与头孢曲松钠发生降解反应生成蛋白酶体,放出气体,其化合物蛋白酶体具有消肿止痛作用。
d,取1片0.8g/片的健胃消食片放入砸药罐内,用木棒把药片碾碎成为药粉,倒入10毫升带橡皮塞的玻璃瓶内,用5ml注射器吸取3ml氯化钠注射液注入玻璃瓶内,用手摇后静止30分钟,有沉淀物析出,上部的悬乳液-健胃消食片颗粒水溶液,按药片的溶解量20%计算,该药液浓度为0.15g/ml。用5ml注射器取出1ml注入至步骤2)中所述的1个聚乙烯瓶内,震荡后放置48小时。消食片中的山楂所含的酒石酸与头孢曲松钠发生中和反应而生成酒石酸钠沉淀物放出热,常温放置30天备用。
本发明的药物对肿瘤疾病作用,肿瘤可以呈膨胀性生长、外生性生长和浸润性生长。
1)膨胀性生长:是大多数良性肿瘤所表现的生长方式,肿瘤生长缓慢,不侵袭周围组织,这时只采用少量口服本发明的药物。
2)外生性生长:发生在体表、体腔表面或管道器官(如消化道、泌尿生殖道)表面的肿瘤,常向表面生长,形成突起的乳头状、息肉状、菜花状的肿物,良性、恶性肿瘤都可呈外生性生长。此种情况,采用内外同时用本发明的药,恶性肿瘤者内服药量2~4ml。
3)浸润性生长:为大多数恶性肿瘤的生长方式。由于肿瘤生长迅速,侵入周围组织间隙、淋巴管、血管。此种情况,采用内外同时用药,并附加罗红霉素和头孢克洛抗生素,与该本发明的药间隔2小时口服的治疗方法,消除浸润在组织内的病毒,恢复组织功能。
e,.药品的检验:当跳蚤在腰部几处叮咬时,会出现红肿块,奇痒难受。用药液在患处,每日3次,3日以后症状消失。
下面以食管癌为例来说明本发明药物的药理作用。
内科学第四篇/消化系统疾病/食管癌(carcinoma of the esophagus)是原发于食管的恶性肿瘤,以鳞状上皮癌多见,临床上以进行性吞咽困难为其最典型的症状。本病是世界一些国家和地区常见的恶性肿瘤。中国是世界上食管癌的高发国家,也是世界上食管癌高死亡率的国家之一,年平均死亡率为1.3~90.9/10万,而世界人口标化死亡率为2.7~110.06/10万。本病发病率有地区、性别、年龄差别。
柳青麻21岁,2009年10月15日,在人民医院复诊。
主诉:咽部疼痛、吞咽困难、胸骨后不适、烧灼感。
X线检查:食管癌X线钡餐造影的征象有1)黏膜皱襞增厚,迂曲及中断;2)食管边缘毛刺状;3)局限性管壁僵硬或有钡剂滞留,属于早期症状。食管癌位于食管上段、病变长度超过5cm、已侵犯食管肌层、癌细胞分化程度差。
病因:食管癌的确切病因目前尚不清楚,于下列因素有关:亚硝铵类化合物和真菌毒素、饮食刺激和食管慢性刺激、营养因素、癌基因、人乳头状病毒,乳多空病毒有关。
治疗:将本发明的药液滴入口腔内,每次2ml,2次/日,使用12~15日,治愈疾病。治疗期间,不易食辛辣油腻解毒的食物,以免降低药物疗效。
Claims (6)
1.一种治疗肿瘤疾病的中西复合药,其特征在于:它由中药成分和西药成分混合组成,中药成分包括多酶片和健胃消食片,多酶片由胃蛋白酶、胰蛋白酶、胰淀粉酶、胰脂肪酶组成,健胃消食片由太子参、陈皮、山药、(炒)麦芽、山楂(含酒石酸)组成;西药成分是头孢曲松钠针剂;所述各组分的用量-中药:0.313g/片多酶片5片、计1.57g,0.8g/片健胃消食片1片、计0.8g,西药:0.75g/支头孢曲松钠针剂1支、计0.75g,将以上成分的中西药物组合,形成一方剂。
2.根据权利要求1所述的治疗肿瘤疾病的中西复合药,其特征在于:该药的制备方法如下,
1)首先原料和器具如下:浓度为250ml:2.25g的氯化钠注射液1瓶,5ml及10ml的配药注射器各1个,带橡皮塞的10ml玻璃瓶1个,10ml聚乙烯瓶1个,砸药罐和药勺各1个。
2)取0.313g/片的多酶片5片,用药勺把药片放入砸药罐内,用木棒把药片碾碎成为药粉,倒入10毫升带橡皮塞的玻璃瓶内;再使用10ml注射器分2次吸取6ml氯化钠注射液注入带橡皮塞的玻璃瓶内,用手摇晃使其充分溶解,然后静置30分钟;有沉淀物析出,上部为暗红色的悬乳液-多酶片水溶液,按药片的溶解量20%计算,该药水溶液的浓度为0.1g/ml,用5ml注射器将该药液吸出4ml,注入到10ml的聚乙烯瓶内。
3)取0.75g/支的头孢曲松钠针剂1支,撬掉铝盖,用10ml注射器2次吸入8ml氯化钠注射液注入瓶中,震荡后5分钟,放置48小时后;药液呈现浅红色,其浓度为0.09g/ml,用5ml注射器吸出1.5ml药液注入至步骤2)中所述的1个聚乙烯瓶内,震荡后放置24小时。多酶片中胰蛋白酶、胃蛋白酶与头孢曲松钠发生降解反应生成蛋白酶体,放出气体,其化合物蛋白酶体具有消肿止痛作用。
4)取1片0.8g/片的健胃消食片放入砸药罐内,用木棒把药片碾碎成为药粉,倒入10毫升带橡皮塞的玻璃瓶内,用5ml注射器吸取3ml氯化钠注射液注入玻璃瓶内,用手摇后静止30分钟,有沉淀物析出,上部的悬乳液-健胃消食片颗粒水溶液,按药片的溶解量20%计算,该药液浓度为0.15g/ml。用5ml注射器取出1ml注入至步骤2)中所述的1个聚乙烯瓶内,震荡后放置48小时。消食片中的山楂所含的酒石酸与头孢曲松钠发生中和反应而生成酒石酸钠沉淀物放出热,常温放置30天备用。
验证:头孢曲松钠药液与健胃消食片悬乳液中山楂成分发生反应。取一个10ml聚乙烯瓶,用5ml的注射器吸取3ml氯化钠生理盐水注入另一个聚乙烯瓶内,再用5ml的注射器吸取1ml的头孢曲松钠药液注入聚乙烯瓶内;把凉干的山楂切片,用刀片切成碎片10个,放入聚乙烯瓶内。用力震荡5分钟后加盖放置48小时,可以看到聚乙烯瓶内山楂片的表面有许多小气泡,打开瓶盖时有气体放出。山楂的成分有山楂酸、酒石酸、柠檬酸、苹果酸,其中酒石酸的化学活性较强。可以证明头孢曲松钠药液与健胃消食片悬乳液中山楂中的酒石酸发生反应。
3.根据权利要求1所述的治疗肿瘤疾病的中西复合药,其特征在于:所述的“健胃消食片”系市面购买江西南昌江中药业股份有限公司所生产,“多酶片”系市面购买四川蜀中制药厂所生产,“头孢曲松钠针剂”系市面购买山东鲁抗股份有限公司所生产。
4.根据权利要求1所述的治疗肿瘤疾病的中西复合药,其特征在于:本发明的中药成分多酶片由胃蛋白酶、胰蛋白酶、胰淀粉酶、胰脂肪酶组成,功能主治:用于消化不良,食欲缺乏。中药健胃消食片的主要成分由太子参、陈皮、山药、麦芽(炒)、山楂,功能主治:健胃消食。
1)中药健胃消食片中的山药根茎含多巴胺、儿茶酚胺(catecholamine),以及胆甾醇(cholesterol),麦角甾醇(ergosterol),菜油甾醇(campesterol),豆甾醇(stigmasterol),β-谷甾醇(β-sitosterol)。粘液中含植酸(phytic acid),甘露多糖(mannan)Ia,Ib和Ic;还有三萜皂甙,尿囊素,胆碱(choline),17种氨基酸。
在所有来源于植物种子的油脂中含有甾醇,植物性甾醇不溶于水、酸和碱,但可以溶于乙醚、苯、氯仿、乙酸乙脂、石油醚等有机溶剂。山药甾醇具有阻断致癌物诱发癌细胞形成的功能,β-谷甾醇等植物甾醇对大肠癌、皮肤癌、宫颈癌的发生具有一定程度的抑制作用,疗效很低。
2)中药健胃消食片中的山楂含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等,还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质,所含的解脂酶能促进脂肪类食物的消化。
中药健胃消食片山楂中L-苹果酸可以用于治疗肝病、贫血、免疫力低下、尿毒症、高血压、肝衰竭等多种疾病,并能减轻抗癌药物对正常细胞的毒害作用。
中药健胃消食片山楂中黄酮类化合物含有的牡荆索具有抗癌作用,常用山楂有利于防癌。据报道,山楂片水煎液可延长长瘤动物的寿命,如可抑制小鼠艾氏腹水癌细胞作用,对人的子宫颈癌TCC-26抑制率达70%;鲜山植具抗噬菌体作用,说明有抗癌活性;对子宫癌早期患者恶露不尽,大肠癌等,既能健胃利肠;又有抗癌通淤作用。
3)麦芽主要含α-及β-淀粉酶(amylase),催化酶(catalyticase),过氧化异构酶(peroxidisomerase)另含大麦芽碱(hordenine),大麦芽胍碱(hordatine)A、B,腺嘌呤(ade-nine)胆碱(choline),蛋白质,氨基酸,维生素D、D、E,细胞色素(cytochrome)C。尚含麦芽毒毒,即白栝楼碱(candici-ne)。功效:消食化积:回乳。
4)多酶片是消化酶制剂,每片含胃蛋白酶13克,胰酶300毫克,辅料为硬脂酸镁、滑石粉、邻苯二甲酸二乙脂等。其中胰酶含有胰蛋白酶、胰淀粉酶、胰脂肪酶等组成,通常用于治疗消化酶缺乏的消化不良症。
药理作用:胰脂肪酶能使脂肪分解为甘油及脂肪酸,胰淀粉酶能使淀粉转化为糖,胰蛋白酶能消化溶解变性蛋质,因此,能使脓、痰液、血凝块等分解、变稀,易于引流排除,加速创面净化,促进肉芽组织新生,此外还有抗炎症作用。用于呼吸道疾病,也可用于治疗毒蛇咬伤。胰蛋白酶能使蛋白质转化为蛋白胨;胃蛋白酶(英文名称:Pepsin)是一种消化性蛋白酶,由胃部中的胃粘膜主细胞所分泌,功能是将食物中的蛋白质分解为小的肽片段。胃蛋白酶能使蛋白质转化为蛋白及蛋白胨。
5.根据权利要求1所述的治疗肿瘤疾病的中西复合药,其特征在于:西药头孢曲松钠药理作用头孢曲松钠的分子式为C18H16N8Na2O7S3?3H2O,分子量为661、59。本品为白色或类白色结晶粉末。本品为长效、广谱头孢菌素,具有很强的杀菌作用。用于敏感致病菌所致的下呼吸道感染、尿路、胆道感染,以及腹腔感染、盆腔感染、皮肤软组织感染、骨和关节感染、败血症、脑膜炎等及手术期感染预防。头孢曲松钠不良反应与治疗的剂量、疗程有关。局部反应有静脉炎(1.86%),此外可有皮疹、头痛或头晕(0.27%),腹泻、恶心、呕吐、腹痛、结肠炎、黄疸、胀气、味觉障碍和消化不良等消化道反应(3.45%)。
药物相互作用:头孢菌素类(注射用头孢曲松钠)静脉输液中加入红霉素、四环素、两性霉素B、血管活性药(间羟胺、去甲肾上腺素等)、苯妥英钠、氯丙嗪、异丙醇、维生素B族、维生素C等时将出现混浊。由于本品的配伍禁忌药物甚多,所以应单独给药。2应用本品期间饮酒或服含酒精药物时在个别病人可出现双硫仑样反应,应避免饮酒和服含酒精的药物。本品与含钙剂或含钙产品合并用药有可能导致致死性事件。
6.根据权利要求1所述的治疗肿瘤疾病的中西复合药,其特征在于:本发明药物的特性,多酶片中胰蛋白酶、胃蛋白酶与头孢曲松钠发生裂解反应生成蛋白酶体,其功效具有抑制乳多空病毒、大肠埃希菌、肺炎克雷伯菌引起恶性和良性肿瘤。山药中的甾醇类物质和山楂中的黄酮类化合物含有的牡荆素物质与蛋白酶体协同增效,用于水性和脓性肿瘤。胰蛋白酶能消化溶解变性蛋质,因此,能使脓、痰液、血凝块等分解、变稀,易于引流排除,中药健胃消食片山楂中L-苹果酸可以用于治疗肝病、贫血、免疫力低下、尿毒症、高血压、肝衰竭等多种,并能减轻抗癌药物对正常细胞的毒害作用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110249389XA CN102949712A (zh) | 2011-08-21 | 2011-08-21 | 一种治疗肿瘤疾病的中西复合药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110249389XA CN102949712A (zh) | 2011-08-21 | 2011-08-21 | 一种治疗肿瘤疾病的中西复合药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102949712A true CN102949712A (zh) | 2013-03-06 |
Family
ID=47759472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110249389XA Pending CN102949712A (zh) | 2011-08-21 | 2011-08-21 | 一种治疗肿瘤疾病的中西复合药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102949712A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016538339A (ja) * | 2013-11-18 | 2016-12-08 | トルンカ フランチシェク | プロ酵素及び酵素の混合物を含む医薬組成物 |
CN106860860A (zh) * | 2017-03-03 | 2017-06-20 | 钱安坤 | 多酶片的新应用 |
CN112569240A (zh) * | 2019-09-29 | 2021-03-30 | 四川大学华西医院 | 盐酸氯丙嗪在制备细胞周期素蛋白抑制剂中的用途 |
-
2011
- 2011-08-21 CN CN201110249389XA patent/CN102949712A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016538339A (ja) * | 2013-11-18 | 2016-12-08 | トルンカ フランチシェク | プロ酵素及び酵素の混合物を含む医薬組成物 |
US11185587B2 (en) | 2013-11-18 | 2021-11-30 | Frantisek Trnka | Pharmaceutical composition containing a mixture of proenzymes and enzymes |
CN106860860A (zh) * | 2017-03-03 | 2017-06-20 | 钱安坤 | 多酶片的新应用 |
CN112569240A (zh) * | 2019-09-29 | 2021-03-30 | 四川大学华西医院 | 盐酸氯丙嗪在制备细胞周期素蛋白抑制剂中的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103385260B (zh) | 一种检验科用杀菌药物及制备方法 | |
CN105362295A (zh) | 一种治疗急慢性咽喉炎、口腔溃疡的美洲大蠊药物组合物及其制备方法 | |
RU2419449C1 (ru) | Средство для лечения больных лекарственным гепатитом | |
CN105664140A (zh) | 一种糖肽组合物及其制备方法和用途 | |
CN102949712A (zh) | 一种治疗肿瘤疾病的中西复合药物 | |
CN102846667A (zh) | 一种经低温干燥制备纳米美洲大蠊的制备方法 | |
CN105662996A (zh) | 治疗月经相关性痤疮的中药面膜 | |
CN101837045A (zh) | 一种治疗口腔溃疡的美洲大蠊药物组合物及其制备方法 | |
CN106377602A (zh) | 一种铁皮石斛复合消毒粉及制备方法和使用方法 | |
CN104474528B (zh) | 用于引流排毒的药物 | |
CN102805743A (zh) | 牛蒡苷元在治疗血管生成性疾病中的应用 | |
CN102793870B (zh) | 一种治疗肾结石的中草药 | |
CN102166334B (zh) | 一种治疗婴儿湿疹和老年皮肤瘙痒的外用药及其制法 | |
CN102846750B (zh) | 风痛宁复合制剂及其制备方法 | |
CN110917249A (zh) | 一种用于前列腺的中药组合物及其制备方法和应用 | |
CN117462620B (zh) | 一种治疗肺癌的中药组方及制备方法和应用 | |
CN103705706B (zh) | 一种治疗乳腺疾病的药物及其制备方法 | |
CN102784344B (zh) | 一种治疗肺结核的中药制剂 | |
RU2391995C1 (ru) | Средство для лечения злокачественных и доброкачественных новообразований различной локализации | |
AU2019201371B2 (en) | Composition of combined plant proteins for treatment of cancer and diabetes | |
CN101244138B (zh) | 一种治疗冻伤的外用中药制剂 | |
CN101879187A (zh) | 一种敛疮生肌的薄板烧烫伤膏及其制备方法 | |
CN107320547B (zh) | 一种治疗食管癌的药物及其制备方法 | |
CN104887702A (zh) | 一种治疗皮肤外伤及溃烂的中药组合物及其制备方法 | |
KR20170120375A (ko) | 한약 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130306 |